UniProt ID | NELFE_HUMAN | |
---|---|---|
UniProt AC | P18615 | |
Protein Name | Negative elongation factor E | |
Gene Name | NELFE | |
Organism | Homo sapiens (Human). | |
Sequence Length | 380 | |
Subcellular Localization | Nucleus. | |
Protein Description | Essential component of the NELF complex, a complex that negatively regulates the elongation of transcription by RNA polymerase II. The NELF complex, which acts via an association with the DSIF complex and causes transcriptional pausing, is counteracted by the P-TEFb kinase complex. The NELF complex is involved in HIV-1 latency possibly involving recruitment of PCF11 to paused RNA polymerase II. Provides the strongest RNA binding activity of the NELF complex and may initially recruit the NELF complex to RNA. Binds to the HIV-1 TAR RNA which is located in the long terminal repeat (LTR) of HIV-1.. | |
Protein Sequence | MLVIPPGLSEEEEALQKKFNKLKKKKKALLALKKQSSSSTTSQGGVKRSLSEQPVMDTATATEQAKQLVKSGAISAIKAETKNSGFKRSRTLEGKLKDPEKGPVPTFQPFQRSISADDDLQESSRRPQRKSLYESFVSSSDRLRELGPDGEEAEGPGAGDGPPRSFDWGYEERSGAHSSASPPRSRSRDRSHERNRDRDRDRERDRDRDRDRDRERDRDRDRDRDRDRERDRDRERDRDRDREGPFRRSDSFPERRAPRKGNTLYVYGEDMTPTLLRGAFSPFGNIIDLSMDPPRNCAFVTYEKMESADQAVAELNGTQVESVQLKVNIARKQPMLDAATGKSVWGSLAVQNSPKGCHRDKRTQIVYSDDVYKENLVDGF | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
9 | Phosphorylation | LVIPPGLSEEEEALQ CCCCCCCCHHHHHHH | 49.21 | 28122231 | |
33 | 2-Hydroxyisobutyrylation | KKALLALKKQSSSST HHHHHHHHHHCCCCC | 43.06 | - | |
33 | Acetylation | KKALLALKKQSSSST HHHHHHHHHHCCCCC | 43.06 | 25953088 | |
36 | Phosphorylation | LLALKKQSSSSTTSQ HHHHHHHCCCCCCCC | 40.86 | 28348404 | |
37 | Phosphorylation | LALKKQSSSSTTSQG HHHHHHCCCCCCCCC | 26.30 | 22496350 | |
38 | Phosphorylation | ALKKQSSSSTTSQGG HHHHHCCCCCCCCCC | 36.63 | 28348404 | |
39 | Phosphorylation | LKKQSSSSTTSQGGV HHHHCCCCCCCCCCC | 37.34 | 28348404 | |
40 | Phosphorylation | KKQSSSSTTSQGGVK HHHCCCCCCCCCCCC | 32.20 | 28348404 | |
41 | Phosphorylation | KQSSSSTTSQGGVKR HHCCCCCCCCCCCCC | 22.47 | 24114839 | |
42 | Phosphorylation | QSSSSTTSQGGVKRS HCCCCCCCCCCCCCC | 27.24 | 24114839 | |
47 | Sumoylation | TTSQGGVKRSLSEQP CCCCCCCCCCCCCCC | 39.27 | - | |
47 | Sumoylation | TTSQGGVKRSLSEQP CCCCCCCCCCCCCCC | 39.27 | - | |
49 | Phosphorylation | SQGGVKRSLSEQPVM CCCCCCCCCCCCCCC | 30.45 | 29255136 | |
51 | Phosphorylation | GGVKRSLSEQPVMDT CCCCCCCCCCCCCCC | 35.12 | 29255136 | |
56 | Sulfoxidation | SLSEQPVMDTATATE CCCCCCCCCCHHHHH | 4.89 | 21406390 | |
58 | Phosphorylation | SEQPVMDTATATEQA CCCCCCCCHHHHHHH | 14.07 | 30266825 | |
60 | Phosphorylation | QPVMDTATATEQAKQ CCCCCCHHHHHHHHH | 35.88 | 30266825 | |
62 | Phosphorylation | VMDTATATEQAKQLV CCCCHHHHHHHHHHH | 25.03 | 23927012 | |
71 | Phosphorylation | QAKQLVKSGAISAIK HHHHHHHHCCHHHHE | 26.44 | 25159151 | |
75 | Phosphorylation | LVKSGAISAIKAETK HHHHCCHHHHEEHHC | 24.33 | 25159151 | |
78 | Sumoylation | SGAISAIKAETKNSG HCCHHHHEEHHCCCC | 39.63 | - | |
78 | Sumoylation | SGAISAIKAETKNSG HCCHHHHEEHHCCCC | 39.63 | 25114211 | |
78 | Acetylation | SGAISAIKAETKNSG HCCHHHHEEHHCCCC | 39.63 | 25953088 | |
82 | Sumoylation | SAIKAETKNSGFKRS HHHEEHHCCCCCCCC | 40.39 | 28112733 | |
84 | Phosphorylation | IKAETKNSGFKRSRT HEEHHCCCCCCCCEE | 47.35 | 21857030 | |
89 | Phosphorylation | KNSGFKRSRTLEGKL CCCCCCCCEEECCCC | 30.15 | 22817900 | |
91 | Phosphorylation | SGFKRSRTLEGKLKD CCCCCCEEECCCCCC | 30.33 | 29900121 | |
95 | Ubiquitination | RSRTLEGKLKDPEKG CCEEECCCCCCCCCC | 42.88 | - | |
97 | Acetylation | RTLEGKLKDPEKGPV EEECCCCCCCCCCCC | 74.79 | 25953088 | |
101 | Acetylation | GKLKDPEKGPVPTFQ CCCCCCCCCCCCCCC | 74.11 | 25953088 | |
106 | Phosphorylation | PEKGPVPTFQPFQRS CCCCCCCCCCCCCCC | 34.83 | 26074081 | |
113 | Phosphorylation | TFQPFQRSISADDDL CCCCCCCCCCCCCCH | 15.31 | 22167270 | |
115 | Phosphorylation | QPFQRSISADDDLQE CCCCCCCCCCCCHHH | 27.22 | 19664994 | |
123 | Phosphorylation | ADDDLQESSRRPQRK CCCCHHHHCCCHHHH | 19.04 | 25159151 | |
124 | Phosphorylation | DDDLQESSRRPQRKS CCCHHHHCCCHHHHH | 31.40 | 23927012 | |
130 | Ubiquitination | SSRRPQRKSLYESFV HCCCHHHHHHHHHHH | 39.30 | 21890473 | |
130 | Ubiquitination | SSRRPQRKSLYESFV HCCCHHHHHHHHHHH | 39.30 | 21890473 | |
131 | Phosphorylation | SRRPQRKSLYESFVS CCCHHHHHHHHHHHC | 38.07 | 25159151 | |
133 | Phosphorylation | RPQRKSLYESFVSSS CHHHHHHHHHHHCCH | 19.33 | 22167270 | |
135 | Phosphorylation | QRKSLYESFVSSSDR HHHHHHHHHHCCHHH | 19.86 | 23927012 | |
138 | Phosphorylation | SLYESFVSSSDRLRE HHHHHHHCCHHHHHH | 23.32 | 23927012 | |
139 | Phosphorylation | LYESFVSSSDRLREL HHHHHHCCHHHHHHH | 30.84 | 23927012 | |
140 | Phosphorylation | YESFVSSSDRLRELG HHHHHCCHHHHHHHC | 21.17 | 23927012 | |
142 | Methylation | SFVSSSDRLRELGPD HHHCCHHHHHHHCCC | 37.28 | 115490999 | |
165 | Phosphorylation | AGDGPPRSFDWGYEE CCCCCCCCCCCCCCC | 33.07 | 22115753 | |
170 | Phosphorylation | PRSFDWGYEERSGAH CCCCCCCCCCCCCCC | 15.46 | 28796482 | |
174 | Phosphorylation | DWGYEERSGAHSSAS CCCCCCCCCCCCCCC | 43.54 | 30266825 | |
178 | Phosphorylation | EERSGAHSSASPPRS CCCCCCCCCCCCCCC | 27.37 | 30266825 | |
179 | Phosphorylation | ERSGAHSSASPPRSR CCCCCCCCCCCCCCC | 23.93 | 23927012 | |
181 | Phosphorylation | SGAHSSASPPRSRSR CCCCCCCCCCCCCCC | 37.07 | 23927012 | |
185 | Phosphorylation | SSASPPRSRSRDRSH CCCCCCCCCCCCCCH | 40.14 | 26055452 | |
187 | Phosphorylation | ASPPRSRSRDRSHER CCCCCCCCCCCCHHH | 39.52 | 28464451 | |
191 | Phosphorylation | RSRSRDRSHERNRDR CCCCCCCCHHHHHHH | 33.71 | 20068231 | |
249 | Phosphorylation | REGPFRRSDSFPERR CCCCCCCCCCCCCCC | 33.09 | 30266825 | |
251 | Phosphorylation | GPFRRSDSFPERRAP CCCCCCCCCCCCCCC | 43.90 | 25159151 | |
263 | Phosphorylation | RAPRKGNTLYVYGED CCCCCCCEEEEECCC | 28.30 | 29978859 | |
265 | Phosphorylation | PRKGNTLYVYGEDMT CCCCCEEEEECCCCC | 6.92 | 18669648 | |
267 | Phosphorylation | KGNTLYVYGEDMTPT CCCEEEEECCCCCHH | 10.97 | 18669648 | |
272 | Phosphorylation | YVYGEDMTPTLLRGA EEECCCCCHHHHCCC | 25.99 | 25159151 | |
274 | Phosphorylation | YGEDMTPTLLRGAFS ECCCCCHHHHCCCCC | 29.29 | 21082442 | |
281 | Phosphorylation | TLLRGAFSPFGNIID HHHCCCCCCCCCEEE | 20.84 | 25159151 | |
332 | Ubiquitination | LKVNIARKQPMLDAA EEEEHHHHCCCCHHH | 50.13 | - | |
340 | Phosphorylation | QPMLDAATGKSVWGS CCCCHHHCCCCHHHH | 47.03 | 20044836 | |
343 | Phosphorylation | LDAATGKSVWGSLAV CHHHCCCCHHHHHHH | 25.17 | 26074081 | |
347 | Phosphorylation | TGKSVWGSLAVQNSP CCCCHHHHHHHCCCC | 9.46 | 20044836 | |
353 | Phosphorylation | GSLAVQNSPKGCHRD HHHHHCCCCCCCCCC | 15.76 | 19664994 | |
363 | Phosphorylation | GCHRDKRTQIVYSDD CCCCCCCCEEEECCC | 28.52 | 22210691 | |
367 | Phosphorylation | DKRTQIVYSDDVYKE CCCCEEEECCCHHHH | 14.17 | 25159151 | |
368 | Phosphorylation | KRTQIVYSDDVYKEN CCCEEEECCCHHHHH | 19.21 | 28387310 | |
372 | Phosphorylation | IVYSDDVYKENLVDG EEECCCHHHHHCCCC | 21.41 | 22210691 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
51 | S | Phosphorylation | Kinase | MAPKAPK2 | P49137 | PSP |
115 | S | Phosphorylation | Kinase | MAPKAPK2 | P49137 | PSP |
131 | S | Phosphorylation | Kinase | AURKB | Q96GD4 | GPS |
251 | S | Phosphorylation | Kinase | MAPKAPK2 | P49137 | PSP |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of NELFE_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NELFE_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51; SER-131 AND SER-353,AND MASS SPECTROMETRY. | |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASSSPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-353, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-131; SER-251;TYR-265; TYR-267; THR-272; THR-274; SER-281 AND SER-353, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASSSPECTROMETRY. | |
"Combining protein-based IMAC, peptide-based IMAC, and MudPIT forefficient phosphoproteomic analysis."; Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,Yates J.R. III; J. Proteome Res. 7:1346-1351(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131 AND SER-281, ANDMASS SPECTROMETRY. | |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51, AND MASSSPECTROMETRY. | |
"Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis."; Wang B., Malik R., Nigg E.A., Korner R.; Anal. Chem. 80:9526-9533(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASSSPECTROMETRY. | |
"Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181, AND MASSSPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-353, ANDMASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-191, ANDMASS SPECTROMETRY. | |
"Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASSSPECTROMETRY. |